Colin Bristow

Stock Analyst at UBS

(0)
# 4893
Out of 5,328 analysts
96
Total ratings
21.62%
Success rate
-28.28%
Average return
23 Stocks
Name Action PT Current % Upside Ratings Updated
IMVT Immunovant
Downgrades: Neutral
38 17
16.14 5.33% 6 Apr 22, 2025
AMGN Amgen
Maintains: Neutral
315 319
284.76 12.02% 8 Apr 14, 2025
ABOS Acumen Pharmaceutica...
Maintains: Buy
6 4
1.06 277.36% 4 Mar 28, 2025
ENGN enGene Holdings
Downgrades: Neutral
34 7
3.72 88.17% 2 Feb 14, 2025
PFE Pfizer
Maintains: Neutral
29 28
24.03 16.52% 12 Feb 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
4 3
0.52 323.08% 5 Jan 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
125 120
83.39 43.9% 6 Jan 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
47 71
49.26 44.13% 3 Dec 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
70 96
103.48 -7.23% 3 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
562 586
500.59 17.06% 13 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
234 202
121.29 66.54% 10 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
56 16
1.81 783.98% 5 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
1090 1099
586.15 87.49% 1 Apr 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
56 54
7.88 585.28% 2 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
164 167
63.08 164.74% 5 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
428 420
805.81 -47.88% 1 Dec 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
12 2
7.08 -71.75% 2 Dec 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
18
0.9 1900% 1 Oct 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
154 146
193.88 -24.7% 2 Aug 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
73 75
49.72 50.84% 1 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
64 26
1.65 1475.76% 1 Apr 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
9
4.87 84.8% 1 Aug 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
195
n/a n/a 2 Feb 1, 2021